Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience-Reference-Cited by-同舟云学术

Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience

Published:2019-06 Issue:6 Volume:48 Page:1127-1132
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Mooradian Meghan J.,Nasrallah Mazen,Gainor Justin F.,Reynolds Kerry L.,Cohen Justine V.,Lawrence Donald P.,Miloslavsky Eli M.^ORCID,Kohler Minna J.,Sullivan Ryan J.,Schoenfeld Sara R.

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference20 articles.

1. June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med 2017;23(5):540–7.

2. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial;Weber;Lancet Oncol,2016

3. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

4. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

5. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease;European Journal of Cancer;2024-08

2. Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms;Autoimmunity Reviews;2024-07

3. Autoimmune Phenomena in Cancer Patients Treated with Immune Checkpoint Inhibitors;Autoimmune Disorders;2024-05-03

4. Imaging in Rheumatic Immune-related Adverse Events;Rheumatic Disease Clinics of North America;2024-05

5. Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first;Pediatric Rheumatology;2024-04-29